Karan Sheth, PA
Physician Assistant · Columbia, SCNPI 1790404960
Payments from drug & device makers
Across 165 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$584
- Novo Nordisk$459
- AstraZeneca$456
- AbbVie$247
- Amgen$173
- Merck$96
- plus $917 from 23 others
What the payments were for
- Food & beverage$2,933100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 33 | $584 |
| Novo Nordisk | 21 | $459 |
| AstraZeneca | 27 | $456 |
| AbbVie | 15 | $247 |
| Amgen | 12 | $173 |
| Merck | 5 | $96 |
| Exact Sciences | 6 | $95 |
| Novartis | 5 | $90 |
| Radius Health, Inc. | 4 | $65 |
| Lilly USA, LLC | 4 | $60 |
| Xeris Pharmaceuticals, Inc. | 3 | $57 |
| Pfizer | 3 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $46 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Nevro Corp. | 2 | $40 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| Astellas Pharma US Inc | 2 | $34 |
| Ardelyx, Inc. | 2 | $32 |
| Dexcom, Inc. | 2 | $30 |
| Forte Bio-pharma LLC | 2 | $26 |
| Abbott | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Viatris Specialty LLC | 1 | $24 |
| Corcept Therapeutics | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$2,933 in reported general payments places this provider in the 80th percentile of 1,852 physician assistant providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 84 | $152,237 |
| EliquisApixaban | 75 | $88,621 |
| JardianceEmpagliflozin | 62 | $77,809 |
| FarxigaDapagliflozin Propanediol | 57 | $58,113 |
| RybelsusSemaglutide | 22 | $54,392 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $41,678 |
| LinzessLinaclotide | 39 | $38,883 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $34,852 |
| MounjaroTirzepatide | 23 | $34,327 |
| JanuviaSitagliptin Phosphate | 30 | $34,148 |
| RexultiBrexpiprazole | 13 | $22,136 |
| VraylarCariprazine Hcl | 12 | $17,830 |
| OxycontinOxycodone Hcl | 21 | $12,148 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $10,503 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 223 | $6,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $459 | $206,629106 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $456 | $92,96597 claims |
| PfizerEliquis | $53 | $88,62175 claims |
| Boehringer IngelheimJardiance | $16 | $77,80962 claims |
| AbbVieLinzess, Vraylar, Synthroid | $247 | $58,39172 claims |
| GSKTrelegy Ellipta | $584 | $41,67850 claims |
| Lilly USA, LLCMounjaro | $60 | $34,32723 claims |
| MerckJanuvia | $96 | $34,14830 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $42 | $22,13613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,852 physician assistant providers in South Carolina.
Other physician assistant in Columbia
- Eric ShoupColumbia$74K
- Sydney MorrisColumbia$11K
- Janelle HinsonColumbia$11K
- Karen DolezalColumbia$11K
- Benjamin AddyWest Columbia$377K
- Michael OvercashCharleston$210K
- Allison LesterMt Pleasant$163K
- Nicole KeeterFort Mill$129K
- William YoungGreenville$117K
- Stephanie DavisAnderson$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.